Abstract
Idraparinux sodium, a long-acting anti-Factor Xa synthetic pentasaccharide, is under development by Sanofi-Aventis for the potential prevention and treatment of venous thromboembolic events in patients with deep vein thrombosis or pulmonary embolism.
| Original language | English |
|---|---|
| Pages (from-to) | 1028-1034 |
| Number of pages | 7 |
| Journal | IDrugs |
| Volume | 7 |
| Issue number | 11 |
| State | Published - Nov 2004 |
Fingerprint
Dive into the research topics of 'Idraparinux sodium Sanofi-Aventis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver